Maple Rock Capital Partners Inc. Prothena Corp Public LTD CO Transaction History

Maple Rock Capital Partners Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$32.31 - $52.32 $4.49 Million - $7.27 Million	139,000 Added 59.25%	373,584 $13.6 Million
Q2 2023 Aug 14, 2023	SELL	$48.26 - $78.59 $2.85 Million - $4.64 Million	-59,000 Reduced 20.1%	234,584 $16 Million
Q1 2023 May 15, 2023	SELL	$46.97 - $58.27 $4.97 Million - $6.17 Million	-105,830 Reduced 26.5%	293,584 $14.2 Million
Q3 2022 Nov 14, 2022	BUY	$25.16 - $60.63 $1.65 Million - $3.97 Million	65,414 Added 19.59%	399,414 $24.2 Million
Q1 2022 May 16, 2022	BUY	$30.27 - $49.22 $10.1 Million - $16.4 Million	334,000 New	334,000 $12.2 Million

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $698M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Maple Rock Capital Partners Inc., based on Form 13F filings with the SEC.

Stay updated on Maple Rock Capital Partners Inc. with notifications on news.